Jentayu Sustainables' RM23.41M private placement raises disclosure questions
What's the deal? On June 15, 2026, loss-making Malaysian renewable energy group Jentayu SustainablesDealroom has a profile for this one. Try Dealroom → disclosed that Agrobulk HoldingsDealroom has a profile for this one. Try Dealroom → had become its substantial shareholder through a private placement raising RM23.41 million (about $5.7 million).
Agrobulk acquired 45.37 million shares — an 8.33% stake — on April 17, 2026, making it Jentayu's second largest shareholder. The proceeds are earmarked for Project Oriole, a 162 MW run-of-river hydropower plant in Sabah due in September 2029.
Why now? The puzzle is timing: Jentayu disclosed the change nearly two months after the acquisition.
The gap raises questions about whether the delay stemmed from an administrative lapse or late notification by the shareholder. It also prompts another: did Bursa MalaysiaDealroom has a profile for this one. Try Dealroom → seek an explanation?
What it means: Investors expect material shareholding changes to be reported promptly so they can make informed decisions. The delay casts a spotlight on Jentayu's disclosure practices.
A second issue compounds the scrutiny. In late June 2026, Jentayu announced its exit from healthcare, selling its entire stake in Ultimate Forte — operator of the 30-bed Ohana Specialist Hospital in Kuala Lumpur — to Lourdes Medical Centre for RM1.75 million.
Although the deal needed no shareholder approval, Lourdes' sole director had assumed operational control of the hospital more than two months before the disposal was announced.
Jentayu has also faced scrutiny from minority shareholders in 2026 over the same private placement.
The signal: Agrobulk is a corporate investor rather than an institutional fund, and its emergence as Jentayu's second largest shareholder ties a mature renewable energy player to a single backer's commitment to the long-dated Project Oriole. For a company already at odds with minority shareholders over this same placement, repeated disclosure delays risk eroding the investor trust that small-cap firms can least afford to lose.
Read more: Newswav
